Fortrea Holdings Inc. (FTRE) 株式分析

企業概要

Fortrea Holdings Inc. operates as a contract research organization that delivers comprehensive biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device clients on a global scale. The company is positioned within the Healthcare sector, specifically the Biotechnology industry, which implies a focus on innovative drug discovery and clinical development processes rather than direct consumer sales. Fortrea Holdings Inc. currently holds a market capitalization of $877.03M and generates annual revenue of $2.72B, supported by a workforce of 13,871 employees. These valuation and revenue metrics suggest that the company maintains a significant operational footprint within the biopharmaceutical service market, indicating a substantial presence in a high-growth industry despite recent financial challenges.

財務健全性

The company reported revenue of $2.72B over the trailing twelve months, yet it recorded a net income loss of $986.2M, revealing a cost structure where operating expenses significantly outweigh gross profits. Despite the net loss, the company achieved an EBITDA of $41.50M, highlighting a specific operational profitability before financing and non-operating costs that contrasts sharply with the bottom-line result. The business maintains a gross margin of 18.5%, which indicates the profitability of core services before overhead, while the operating margin of 1.3% suggests high administrative or R&D costs are eroding operating profits. The profit margin stands at -36.2%, confirming that the company is currently operating at a substantial net loss relative to its sales volume. On a cash flow basis, Fortrea generated free cash flow of $196.05M, providing a critical buffer for financial flexibility to fund research initiatives or manage working capital needs. However, the balance sheet shows a cash position of $174.60M against total debt of $1.12B, resulting in a debt-to-equity ratio of 198.26, which characterizes the balance sheet as highly leveraged rather than conservative. Liquidity is constrained by a current ratio of 0.98, indicating that current assets do not fully cover current liabilities, suggesting potential short-term liquidity pressure. Furthermore, the return on equity is -102.4% and the return on assets is -0.6%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.

バリュエーション評価

The trailing P/E ratio is listed as N/A due to the negative net income, whereas the forward P/E is 9.91, implying that the market prices in an expectation of significant future earnings normalization or profitability turnaround. The price-to-book ratio is 1.55, suggesting that the market values the company's equity at a premium of 55% above its net asset book value. Alternative valuation metrics such as a price-to-sales ratio of 0.32 and an EV/EBITDA of 43.85 indicate that the stock is priced based on sales multiples and enterprise value relative to cash flow rather than traditional earnings multiples. The stock has traded between a 52-week high of $18.67 and a 52-week low of $3.97, with the current price implied by the market cap and share structure sitting in a volatile range relative to this historical band. The beta of 1.77 indicates that the stock exhibits high price volatility, moving with significantly greater magnitude than the broader market index.

Growth & Income

Fortrea Holdings Inc. experienced a revenue decline of -5.2% year-over-year, while earnings growth is N/A due to the negative earnings base, implying that revenue contraction has not yet been matched by a proportional improvement in profitability metrics. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company retains all earnings and cash flow for reinvestment into growth initiatives rather than distributing income to shareholders. This non-dividend profile aligns with the biotechnology industry standard for development-stage or cash-burning companies that prioritize R&D and operational scaling over shareholder distributions. Overall, the growth and income profile for Fortrea is defined by revenue contraction and a complete reliance on capital markets or internal cash reserves to fund operations, with no current income generation through dividends.